Foghorn Therapeutics (FHTX) Revenue & Revenue Breakdown
Foghorn Therapeutics Revenue Highlights
Latest Revenue (Y)
$34.16M
Latest Revenue (Q)
$6.89M
Foghorn Therapeutics Revenue by Period
Foghorn Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $34.16M | 77.63% |
| 2022-12-31 | $19.23M | 1357.77% |
| 2021-12-31 | $1.32M | 206.74% |
| 2020-12-31 | $430.00K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Foghorn Therapeutics generated $34.16M in revenue during NA 2023, up 77.63% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Foghorn Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $6.89M | 36.40% |
| 2024-03-31 | $5.05M | -12.46% |
| 2023-12-31 | $5.77M | -66.99% |
| 2023-09-30 | $17.48M | 212.16% |
| 2023-06-30 | $5.60M | 5.46% |
| 2023-03-31 | $5.31M | 26.89% |
| 2022-12-31 | $4.18M | -36.93% |
| 2022-09-30 | $6.63M | 47.75% |
| 2022-06-30 | $4.49M | 14.54% |
| 2022-03-31 | $3.92M | 449.79% |
| 2021-12-31 | $713.00K | 1639.02% |
| 2021-09-30 | $41.00K | -85.30% |
| 2021-06-30 | $279.00K | -2.45% |
| 2021-03-31 | $286.00K | 13.94% |
| 2020-12-31 | $251.00K | 40.22% |
| 2020-09-30 | $179.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Foghorn Therapeutics generated $6.89M in revenue during Q2 2024, up 36.40% compared to the previous quarter, and up 129.74% compared to the same period a year ago.
Foghorn Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| CGEM | Cullinan Oncology | - | - |
| RZLT | Rezolute | - | - |
| CCCC | C4 Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| PRLD | Prelude Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| CSBR | Champions Oncology | - | $12.02M |
FHTX Revenue FAQ
What is Foghorn Therapeutics’s yearly revenue?
Foghorn Therapeutics's yearly revenue for 2023 was $34.16M, representing an increase of 77.63% compared to 2022. The company's yearly revenue for 2022 was $19.23M, representing an increase of 1357.77% compared to 2021. FHTX's yearly revenue for 2021 was $1.32M, representing an increase of 206.74% compared to 2020.
What is Foghorn Therapeutics’s quarterly revenue?
Foghorn Therapeutics's quarterly revenue for Q2 2024 was $6.89M, a 36.40% increase from the previous quarter (Q1 2024), and a 23.02% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.05M, a -12.46% decrease from the previous quarter (Q4 2023), and a -4.88% decrease year-over-year (Q1 2023). FHTX's quarterly revenue for Q4 2023 was $5.77M, a -66.99% decrease from the previous quarter (Q3 2023), and a 37.88% increase year-over-year (Q4 2022).
What is Foghorn Therapeutics’s revenue growth rate?
Foghorn Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 2489.46%, and for the last 5 years (2019-2023) was 0%.